Apellis Pharmaceuticals, Inc. announced that Mikael Dolsten, M.D., Ph.D., has joined the company?s board of directors as of March 1, 2026. Dr. Dolsten brings extensive pharmaceutical research and development experience to the Apellis Board. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.
Prior to Pfizer, Dr. Dolsten held senior research and leadership positions at Wyeth Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, Pharmacia, and Upjohn. He currently serves on the boards of directors of public companies Agilent Technologies, Inc., and Rocket Pharmaceuticals. He is chairman or board director of several private companies including Orbis Medicines, Orogen Therapeutics, Quarry Thera, ChAi Discovery, Enveda Bio and Arbor Biotechnologies.
Dr. Dolsten is also a senior advisor for financially oriented business groups such as Blackstone, GV (Google Ventures), Bain & Company, Sutter Hill Ventures, Canaan Partners and Formation Bio. Dr. Dolsten has published approximately 160 scientific articles and book reviews. He earned his M.D. and Ph.D. from Lund University in Sweden, where he also served as an adjunct professor.
Effective date: March 1, 2026.
